Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors

DiscussionEculizumab potentially offers a mechanism-based treatment of MG in patients under anti-programmed cell death protein 1 (PD-1) agents, without interfering with their mechanism of action and avoiding their discontinuation. Larger case series deserve to be evaluated.
Source: Neurological Sciences - Category: Neurology Source Type: research